Advertisement

Medical and Surgical Options in Thyroid Eye Disease

  • Peter J. Dolman
Chapter

Abstract

Thyroid eye disease (TED) is an immune-mediated disorder causing inflammation and expansion of orbital fat and muscle. The resulting spectrum of ocular and orbital changes may cause significant morbidity and is graded as disease severity. The disease follows a biphasic course with an active or progressive phase followed by a quiescent or stable phase. Appropriate management depends on an accurate and reproducible evaluation system documenting both disease severity and activity: one available method is the VISA classification. Options for managing TED include various medical therapies or radiotherapy—both of which are typically employed during the early progressive stage of the disease—and surgery, which is most commonly used during the quiescent stage, with the exception of surgery in the active phase when vision is threatened due to optic nerve compression or corneal breakdown. The VISA classification provides a logical model for choosing management based on its measurements.

Keywords

Graves’ orbitopathy Thyroid eye disease Thyroid-associated orbitopathy Dysthyroid optic neuropathy Clinical activity score VISA classification Corticosteroids Rituximab Selenium Radiotherapy Orbital decompression Strabismus repair 

References

  1. 1.
    Bahn RS. Graves’ ophthalmopathy. N Engl J Med. 2010;362(8):726–38.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Dolman PJ. Evaluating Graves orbitopathy. Best Pract Res Clin Endocrinol Metab. 2012;26(3):229–48.CrossRefPubMedGoogle Scholar
  3. 3.
    Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid. 1997;7(6):885–9.CrossRefPubMedGoogle Scholar
  4. 4.
    Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994;92:477–588.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Kendall-Taylor P, Perros P. Clinical presentation of thyroid associated orbitopathy. Thyroid. 1998;8:427–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Fatourechi V, Pajouhi M, Fransway AF. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine (Baltimore). 1994;73(1):1–7.CrossRefGoogle Scholar
  7. 7.
    Smith TJ. TSH-receptor-expressing fibrocytes and thyroid-associated ophthalmopathy. Nat Rev Endocrinol. 2015;11:171–81.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Pritchard J, Horst N, Cruikshank W, Smith TJ. Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol. 2002;168:942–50.CrossRefPubMedGoogle Scholar
  9. 9.
    Pritchard J, Han R, Horst N, Cruikshank W, Smith TJ. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor 1 receptor pathway. J Immunol. 2003;170:6348–54.CrossRefPubMedGoogle Scholar
  10. 10.
    Dolman PJ, Rootman J. Ch 18. Predictors of disease severity in thyroid-related orbitopathy. In: Rootman J, editor. Orbital disease. Present status and future challenges. Boca Raton: Taylor and Francis; 2005.Google Scholar
  11. 11.
    Stan MN, Bahn RS. Risk factors for development or deterioration of Graves’ ophthalmopathy. Thyroid. 2010;20:771–83.CrossRefGoogle Scholar
  12. 12.
    Rundle FF. Development and course of exophthalmos and ophthalmoplegia in Graves’ disease with special reference to the effect of thyroidectomy. Clin Sci. 1945;5:177–94.PubMedGoogle Scholar
  13. 13.
    Dolman PJ. Assessment and management plan for Graves’ orbitopathy. In: Bahn RS, editor. Graves’ disease: a comprehensive guide for clinicians. New York: Springer Science + Business Media; 2015.Google Scholar
  14. 14.
    Selva D, Chen C, King G. Late reactivation of thyroid orbitopathy. Clin & Exp Ophthalmol. 2004;32(1):46–50.CrossRefGoogle Scholar
  15. 15.
    Bahn RS, Kazim M. Thyroid eye disease. In: Fay A, Dolman PJ, editors. Diseases and disorders of the orbit and ocular adnexa. London: Elsevier; 2017.Google Scholar
  16. 16.
    Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP. Densities of orbital fat and extraocular muscles in graves orbitopathy patients and controls. Ophthal Plast Reconstr Surg. 2011;27(4):236–40.CrossRefPubMedGoogle Scholar
  17. 17.
    Polito E, Leccisotti A. MRI in Graves orbitopathy; recognition of enlarged muscles and prediction of steroid response. Ophthalmologica. 1995;209:182–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Werner SC. Classification of the eye changes of Graves’ disease. American J Ophthalmology. 1969;68:646–8.CrossRefGoogle Scholar
  19. 19.
    Boboridis K, Perros P. General management plan in Graves’ orbitopathy: a multidisciplinary approach. Basel: Karger; 2007. p. 88–95.CrossRefGoogle Scholar
  20. 20.
    Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin Endocrinol. 1997;47:9.CrossRefGoogle Scholar
  21. 21.
    Martins JRM, Furlanetto RP, Oliveira LM, Mendes A, Passerotti CC, Chiamolera MI, et al. Comparison of practical methods for urinary glycosaminoglycans and serum hyaluronan with clinical activity scores in patients with Graves’ ophthalmopathy. Clin Endocrinol. 2004;60:726–33.CrossRefGoogle Scholar
  22. 22.
    Dolman PJ, Rootman J. VISA classification for Graves orbitopathy. Ophthal Plast Reconstr Surg. 2006;22:319–24.CrossRefPubMedGoogle Scholar
  23. 23.
    Wiersinga WM. Management of Graves’ ophthalmopathy. Nat Clin Pract Endocrinol Metab. 2007;3:396–404.CrossRefPubMedGoogle Scholar
  24. 24.
    Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves’ ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med. 1989;321:1349–52.CrossRefPubMedGoogle Scholar
  25. 25.
    Yang DD, Gonzalez MO, Durairaj VD. Medical management of thyroid eye disease. Saudi J Ophthalmol. 2011;25(1):3–13.CrossRefPubMedGoogle Scholar
  26. 26.
    Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J Clin Endocrinol Metab. 2005;90:5234–40.CrossRefPubMedGoogle Scholar
  27. 27.
    Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves’ ophthalmopathy. Thyroid. 2004;14:403–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol. 2004;88:1380–6.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ ophthalmopathy: systematic review and meta-analysis. J Clin Endocrinol Metab. 2009;94(8):2708–16.CrossRefPubMedGoogle Scholar
  30. 30.
    Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol. 2014;157:1299–305.CrossRefPubMedGoogle Scholar
  31. 31.
    Kahaly G, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W, et al. Cyclosporin and prednisone versus prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Investig. 1986;16:415–22.CrossRefGoogle Scholar
  32. 32.
    Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, et al. Intravenous immunoglobulin versus corticosteroid in treatment of Graves’ ophthalmopathy. Thyroid. 1997;7:579–85.CrossRefPubMedGoogle Scholar
  33. 33.
    Salvi M. Immunotherapy for Graves’ ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014;21:409–14.CrossRefPubMedGoogle Scholar
  34. 34.
    Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS. Randomized controlled trial of rituximab in patients with Graves’ orbitopathy. J Clin Endocrinol Metab. 2015;100:432–41.CrossRefPubMedGoogle Scholar
  35. 35.
    Salvi M, Vannucchi G, Currò N, Campi I, Covelli D, Dazzi D, et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study. J Clin Endocrinol Metab. 2015;100:422–31.CrossRefPubMedGoogle Scholar
  36. 36.
    Marcocci C, Kahaly GJ, Krassas GE, Bartalena L, Prummel M, Stahl M, European Group on Graves’ Orbitopathy, et al. Selenium and the course of mild Graves’ orbitopathy. N Engl J Med. 2011;364:1920–31.CrossRefPubMedGoogle Scholar
  37. 37.
    Dolman PJ, Rath S. Orbital radiotherapy for thyroid eye disease. Curr Opin Ophthalmol. 2012;23(5):427–32.CrossRefPubMedGoogle Scholar
  38. 38.
    Jeon C, Shin JH, Woo KI, Kim YD. Clinical profile and visual outcomes after treatment in patients with dysthyroid optic neuropathy. Korean J Ophthalmol. 2012;26(2):73–9.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Behbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr Opin Ophthalmol. 2004;15:479–82.CrossRefPubMedGoogle Scholar
  40. 40.
    Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Investig. 1991;14:853–60.CrossRefGoogle Scholar
  41. 41.
    Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves’ ophthalmopathy. J Clin Endocrinol Metab. 2004;89:15–20.CrossRefPubMedGoogle Scholar
  42. 42.
    Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves’ orbitopathy: randomised placebo-controlled study. Lancet. 2000;355:1505–9.CrossRefPubMedGoogle Scholar
  43. 43.
    Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves’ ophthalmopathy. Ophthalmology. 2001;108:1523–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Wakelkamp I, Tan H, Saeed P, Schlingemann RO, Verbraak FD, Blank LE, et al. Orbital irradiation for Graves’ ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004;111:1557–62.CrossRefPubMedGoogle Scholar
  45. 45.
    Gillis CC, Chang EH, Al-Kharazi K, Pickles T. Secondary malignancy following radiotherapy for thyroid eye disease. Rep Pract Oncol Radiother. 2016;21(3):156–6.Google Scholar
  46. 46.
    Fayers T, Barker LE, Verity DH, Rose GE. Oscillopsia after lateral wall orbital decompression. Ophthalmology. 2013;120(9):1920–3.CrossRefPubMedGoogle Scholar
  47. 47.
    Fayers T, Dolman PJ. Validity and reliability of the TED-QOL: a new 3-item questionnaire to assess quality of life in thyroid eye disease. Br J Ophthalmol. 2011;95:1670–4.CrossRefPubMedGoogle Scholar
  48. 48.
    Fayers T, Fayers PM, Dolman PJ. Sensitivity and responsiveness of the patient-reported TED-QOL to rehabilitative surgery in thyroid eye disease. Orbit. 2016;35(6):328–34.CrossRefPubMedGoogle Scholar
  49. 49.
    Peragallo JH, Velez FG, Demer JL, Pineles SL. Postoperative drift in patients with thyroid ophthalmopathy undergoing unilateral inferior rectus muscle recession. Strabismus. 2013;21(1):23–8.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Davies MJ, Dolman PJ. Levator muscle enlargement in thyroid eye disease-related upper eyelid retraction. Ophthal Plast Reconstr Surg. 2017;33(1):35–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology. 2010;117(1):133–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Peter J. Dolman
    • 1
  1. 1.Oculoplastics and Orbit, Department of Ophthalmology and Visual SciencesUniversity of British Columbia, Eye Care CenterVancouverCanada

Personalised recommendations